Aerosol characteristics of the eFlow®rapid nebuliser system MMADa): 4,6 µm Respirable Fractiona) < 5 µm: 55 % Aerosol Output Rateb): 0,5 g/min Aerosol data according to ISO 27427; nebulised medium: Salbutamol 2.5 ml. Measured values may vary depending on the medication used. Rec...
The current study identified the impact of formulation variables on the aerosolization performance of the eFlowrapid with special respect to optimized lung application. API formulations (including excipient-supplemented samples) were investigated for physicochemical properties, then nebulized using vibrating-...
167 Inhalation with PARI eFlow® rapid reduces treatment burden significantly in adult CF patients without altering lung functiondoi:10.1016/S1569-1993(07)60153-2R.FischerandS.NaehrigandM.KerscherandR.M.SDOSJournal of Cystic Fibrosis
Objectives To evaluate if vancomycin injections can be successfully nebulised via the Pari LC Plus and eFlow rapid nebulisers, by measuring particle size of droplets produced, proportion and concentration of drug remaining in the nebulis... dMSM Van,J Blissett,GJ Connett,... - 《Archives of ...
The eFlow®rapid nebuliser system with new eBase Controller is suitable for the treatment of a wide range of diseases of the lower airways. It stands for efficient, safe and fast inhalation treatment, combined with even more advantages:
To the Editor: I refer to the article with the title "Changes in Performance of the PARI eFlow[R] Rapid and PARI LC Plus[TM] during 6 Months Use by CF Patients" published in September 2009 by Rottier et al. in the Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 2...
Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv 2009; 22: 263-9.Rottier BL, van Erp CJ, Sluyter TS, Heijerman HG, Frijlink HW, Boer AH. Changes in performance of the Pari eFlow rapid and Pari LC ...
I am somewhat disturbed by the methodology in the recent publication by Rottier et al. discussing the performance of the PARI eFlow Rapid and the PARI LC Plus. For example, they used laser diffraction with the Fraunhofer theory for particle sizing and found the differences between their results ...
Aerosol characteristics of hypertonic saline (HS) nebulised by the eFlow® rapiddoi:10.1016/S1569-1993(08)60106-XE.BitterleandA.LuithlenandK.ReulandD.EBSCO_AspJournal of Cystic Fibrosis
A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eFlow Rapid Nebulizer System in Patients With Cystic FibrosisGenentechBone & Cancer Foundation